BEIJING (Reuters) – China has blocked GSK plc from participating in its national bulk-buy pharmaceutical program from Oct. 31, 2022 to April 29, 2024 due to what it said were recent drug product irregularities, state television CCTV reported on Monday.
(Reporting by Beijing newsroom; editing by Philippa Fletcher)
